PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL

Background: Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have limited treatment options.Methods: R/R DLBCL patients, who were mostly ineligible for ASCT due to age or comorbidities, were treated with maveropepimut-S (MVP-S, previously DPX-Survivac) a survivin directed T cell educating therapy, pembrolizumab, and intermittent low-dose cyclophosphamide.Findings: We identified, using univariate analysis, a subset of patients with enhanced ORR, PFS and DOR. Patients with baseline CD20+/PD-L1 expression had an ORR of 46% (6/13) and the disease control rate was 10/13 (77%). The PFS and OS of the positive CD20+/PD-L1 patients were 7.1 months and 17.4 months, whereas in the intent to-treat (ITT) population of 25 enrolled patients, the ORR was 28% (7/25), median PFS and OS were 4.2 months and 10.1 months respectively. A total of 6/7 clinical responders occurred in CD20+/PD-L1 patients. The regimen was well-tolerated, requiring only minor dose modifications and one discontinuation. Grade 1 or 2 injection site reactions occurred in 14/25, (56%). Statistically significant associations were also seen between PFS and; injection site reactions; and ELISpot response to survivin peptides, both identifying the mechanistic importance of specific immune responses to survivin.Interpretation: This immunotherapy combination was found to be active and safe in this clinically challenging patient population.

Automated summary

A combination therapy of maveropepimut-S, pembrolizumab, and low-dose cyclophosphamide was found to be effective and safe in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Patients with CD20+/PD-L1 expression had higher response rates and longer progression-free survival and duration of response. This treatment regimen had important clinical implications for a challenging patient population.